{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T15:50:47Z","timestamp":1747151447542,"version":"3.40.5"},"reference-count":30,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["IAA number: 244\u201018\u20101067S"],"award-info":[{"award-number":["IAA number: 244\u201018\u20101067S"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>The US Food and Drug Administration monitors the risk of Guillain\u2010Barr\u00e9 syndrome (GBS) following influenza vaccination using several data sources including Medicare. In the 2017 to 2018 season, we transitioned our near real\u2010time surveillance in Medicare to more effectively detect large GBS risk increases early in the season while avoiding false positives.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a simulation study examining the ability of the updating sequential probability ratio test (USPRT) to detect substantially elevated GBS risk in the 8\u2010 to 21\u2010day postvaccination versus 5\u00d7 to 30\u00d7 the historical rate. We varied the first testing week (weeks 5\u20108) and the null rate (1\u00d7\u20103\u00d7) and evaluated power. We estimated signal probability and the risk ratio (RR) after signaling when high\u2010risk seasons were rare.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Applying fixed alternatives, we found &gt;80% power to detect a risk 30\u00d7 the historical rate in week 5 for the 1\u00d7 null and in week 6 for the 1.5\u00d7 to 3\u00d7 nulls. Nearly all testing schedules had &gt;80% power for a 5\u00d7 risk by week 11. To test the robustness of USPRT, we further simulated seasons where 1% were true high\u2010risk seasons. Using a 1\u00d7 null led to 10% of seasons signaling by week 11 (median RR approximately 1.4), which decreased to approximately 1% with the \u22652.5\u00d7 null (median RR approximately 16.0).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>On the basis of the results from this simulation and subsequent consultations with experts and stakeholders, we specified USPRT to test continuously from weeks 7 to 11 using the null hypothesis that the observed GBS rate was 2.5\u00d7 the historical rate. This helped improve the ability of USPRT to provide early detection of GBS risk following influenza vaccination as part of a multilayered system of surveillance.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4807","type":"journal-article","created":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T05:58:20Z","timestamp":1561096700000},"page":"1077-1085","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A simulation study of the statistical power and signaling characteristics of an early season sequential test for influenza vaccine safety"],"prefix":"10.1002","volume":"28","author":[{"given":"Richard A.","family":"Forshee","sequence":"first","affiliation":[{"name":"Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research US Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5491-8392","authenticated-orcid":false,"given":"Mao","family":"Hu","sequence":"additional","affiliation":[{"name":"Acumen LLC  Burlingame California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepa","family":"Arya","sequence":"additional","affiliation":[{"name":"Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research US Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Perez\u2010Vilar","sequence":"additional","affiliation":[{"name":"Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research US Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven A.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research US Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An\u2010Chi","family":"Lo","sequence":"additional","affiliation":[{"name":"Acumen LLC  Burlingame California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeline","family":"Swarr","sequence":"additional","affiliation":[{"name":"Acumen LLC  Burlingame California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Wernecke","sequence":"additional","affiliation":[{"name":"Acumen LLC  Burlingame California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"MaCurdy","sequence":"additional","affiliation":[{"name":"Acumen LLC  Burlingame California USA"},{"name":"Department of Economics Stanford University  Stanford California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Chu","sequence":"additional","affiliation":[{"name":"Center for Medicare Centers for Medicare and Medicaid Services  Baltimore Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Kelman","sequence":"additional","affiliation":[{"name":"Center for Medicare Centers for Medicare and Medicaid Services  Baltimore Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,6,20]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2011.300510"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.06.032"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwt051"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082222"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62189-8"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a112795"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1390"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.03.087"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/sam.11234"},{"key":"e_1_2_9_11_1","unstructured":"MaCurdyT.Updating sequential probability ratio test for real\u2010time surveillance of vaccine\/drug safety. Paper presented at: ASA Biopharmaceutical Section Statistics Workshop;September 13 2012; Washingon D.C."},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70140-7"},{"key":"e_1_2_9_13_1","unstructured":"Explanation of Systems Used by Medicare to Process Your Claims. [Web Article].2012; October 1 2012:https:\/\/www.cms.gov\/Outreach\u2010and\u2010Education\/Medicare\u2010Learning\u2010Network\u2010MLN\/MLNMattersArticles\/downloads\/SE0605.pdf."},{"key":"e_1_2_9_14_1","doi-asserted-by":"crossref","unstructured":"AryaD SaidM IzurietaHS et al.Surveillance for Guillain\u2010Barr\u00e9 Syndrome after 2015\u20102016 and 2016\u20102017 Influenza Vaccination of Medicare Beneficiaries. Unpublished Manuscript.2018.","DOI":"10.1016\/j.vaccine.2019.08.045"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit222"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2010.05.022"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198106253042601"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.20.2217"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1982.03330060038030"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812173392501"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a115974"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/biom.12324"},{"key":"e_1_2_9_23_1","unstructured":"Perez\u2010VilarS WerneckeM AryaD et al.Surveillance for Guillain\u2010Barr\u00e9 syndrome after influenza vaccination among U.S. Medicare beneficiaries during the 2017\u20132018 season. Vaccine. Under Review."},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00339-1"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3966"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.7504"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11009-017-9586-z"},{"key":"e_1_2_9_28_1","doi-asserted-by":"crossref","unstructured":"LeeGM GreeneSK WeintraubES et al. H1N1 and seasonal influenza vaccine safety in the Vaccine Safety Datalink project.2011;41(2):121\u2010128.","DOI":"10.1016\/j.amepre.2011.04.004"},{"key":"e_1_2_9_29_1","doi-asserted-by":"crossref","unstructured":"KulldorffM DavisRL KolczakM LewisE LieuT PlattR J S.A maximized sequential probability ratio test for drug and vaccine safety surveillance.2011;30(1):58\u201078.","DOI":"10.1080\/07474946.2011.539924"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwu322"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix468"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4807","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4807","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.4807","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4807","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T17:40:15Z","timestamp":1694281215000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,20]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1002\/pds.4807"],"URL":"https:\/\/doi.org\/10.1002\/pds.4807","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"type":"print","value":"1053-8569"},{"type":"electronic","value":"1099-1557"}],"subject":[],"published":{"date-parts":[[2019,6,20]]},"assertion":[{"value":"2018-12-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}